Teva and Eagle try to block Bendeka generic
01-07-2021
Fed Circuit affirms generic maker’s win over Eagle
11-05-2020
Eli Lilly and Eagle Pharma settle antitrust and infringement claims
18-12-2019
JHVEPhoto / shutterstock.com
The US Food and Drug Administration (FDA) has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FDA, Eagle Pharmaceuticals, Bendeka, bendamustine, orphan drug, DC Circuit, appeal, blood cancer
